| Product vision |
- Uncomplicated malaria treatment and resistance management
- Potential for prophylaxis
|
| MoA |
- Recent data suggest effect on parasite internal protein secretory pathway. Target not yet fully determined. Decreased susceptibility to ganaplacide is associated with mutations in three P. falciparum genes, CARL (cyclic amine resistance locus), UDP-galactose and Acetyl-CoA transporters
|
| Key features |
Ganaplacide Novel mechanism of action – activity against parasites that are resistant to current drugs Rapid killing of parasites (parasite clearance time <48 hours) Effective against P. falciparum and P. vivax species Transmission-blocking activity in a Standard Membrane Feeding Assay Potential for causal prophylaxis by blocking early liver stage of parasite
Lumefantrine |
| Status |
Phase IIb combination studies ongoing Phase IIb combination study ongoing (recruitment completed) Phase IIb study in paediatric population (KALUMI) ongoing
|
| Next milestone |
|
| Previously |
- Previous names: KAF156, GNF156. Novartis in discovery partnership with MMV, Wellcome Trust, and the Swiss Tropical and Public Health Institute
|
| MMV Project Director |
|
